|Bid||61.80 x 500|
|Ask||62.21 x 2800|
|Day's Range||61.72 - 62.34|
|52 Week Range||57.18 - 66.80|
|PE Ratio (TTM)||39.39|
|Dividend & Yield||1.88 (3.00%)|
|1y Target Est||N/A|
Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in history.